Pfizer releases new real-world evidence showing Paxlovid reduces the risk of COVID-19-related hospitalization by up to 62% in high-risk adults.
Eli Lilly announces FDA approval of donanemab (Kisunla) for adults with early symptomatic Alzheimer's disease, marking a significant milestone in dementia treatment.
Johnson & Johnson reports positive Phase 3 VIVACITY-MG3 trial results for nipocalimab in generalized myasthenia gravis, meeting primary and key secondary endpoints.
Novartis announces FDA approval of Fabhalta (iptacopan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria, offering a convenient treatment alternative.
AstraZeneca presents real-world evidence demonstrating tezepelumab (Tezspire) reduces severe asthma exacerbations by 70% in clinical practice settings.
Merck reports that Keytruda (pembrolizumab) demonstrates a statistically significant overall survival improvement in patients with persistent, recurrent, or metastatic cervical cancer.
AbbVie announces positive Phase 3 FORTIFY maintenance trial results for risankizumab (Skyrizi) in Crohn's disease, demonstrating sustained clinical remission.
Bristol Myers Squibb announces FDA approval of Opdivo (nivolumab) plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.
Gilead Sciences reports groundbreaking PURPOSE 1 trial results showing twice-yearly lenacapavir injection achieves 100% efficacy in preventing HIV in cisgender women.
AbbVie announces long-term data from the ADVANCE and MOTIVATE trials showing Skyrizi (risankizumab) maintains clinical remission in Crohn's disease patients through 52 weeks.
Showing 1–10 of 500 press releases